Ftse Mib
33.427,72
-0,20%
DAX
19.405,20
0,51%
S&P 500
5.987,37
0,30%
NASDAQ
19.054,84
0,27%
Bitcoin
94.653,61
1,68%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ CytoSorbents Corporation (CTSO) CytoSorbents Corporation (CTSO) Notizie

CytoSorbents Corporation

CTSO
0,93
0,01 (1,09%)
26 Nov 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
11/11/202413:30GLOBECytoSorbents And Converge Biotech Announce Strategic..
07/11/202422:10EDGAR2Form 8-K - Current report
07/11/202422:05GLOBECytoSorbents Reports Third Quarter 2024 Financial and..
04/11/202413:00GLOBECytoSorbents Submits Health Canada Medical Device License..
22/10/202413:00GLOBEFDA Accepts DrugSorb-ATR De Novo Application To Reduce the..
17/10/202413:00GLOBECytoSorbents to Report Third Quarter 2024 Operating and..
09/10/202403:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/10/202403:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/10/202423:25EDGAR2Form 8-K - Current report
01/10/202423:22EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
01/10/202414:06EDGAR2Form 8-K - Current report
01/10/202413:00GLOBECytoSorbents Submits DrugSorb-ATR Marketing Application to..
01/10/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
26/9/202423:05EDGAR2Form S-3/A - Registration statement under Securities Act of..
27/8/202413:00GLOBECytoSorbents to Present at the H.C. Wainwright 26ᵗʰ Annual..
20/8/202422:51EDGAR2Form 8-K - Current report
17/8/202400:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/8/202400:57EDGAR2Form 3 - Initial statement of beneficial ownership of..
16/8/202423:28EDGAR2Form S-8 - Securities to be offered to employees in employee..
16/8/202423:12EDGAR2Form 8-K - Current report
16/8/202422:05GLOBECytoSorbents Announces Inducement Grants Under Nasdaq..
13/8/202422:19GLOBECytoSorbents Reports Second Quarter 2024 Financial and..
13/8/202422:18GLOBECytoSorbents Appoints Peter J. Mariani Chief Financial..
13/8/202422:04EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/8/202413:00GLOBECytoSorbents to Report Second Quarter 2024 Operating and..
01/8/202422:12EDGAR2Form 8-K - Current report
01/8/202413:00GLOBECytoSorbents Announces Compliance with Nasdaq Minimum Bid..
29/7/202414:00GLOBECytoSorbents Unveils Newly Redesigned, Unified Company and..
26/7/202423:14EDGAR2Form S-3 - Registration statement under Securities Act of..
26/7/202423:11EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
17/7/202413:00GLOBECytoSorbents to Present at the Inaugural American..
02/7/202413:00GLOBECytoSorbents Secures $20 Million Credit Facility
24/6/202413:00GLOBECytoSorbents Announces Regulatory Approval of CytoSorb® in..
13/6/202413:00GLOBECytoSorbents Announces the Launch and Immediate Availability..
10/6/202422:31EDGAR2Form 8-K - Current report
05/6/202413:00GLOBECytoSorbents to Host its 2024 Virtual Annual Stockholders..
22/5/202422:35EDGAR2Form 8-K - Current report
09/5/202423:23EDGAR2Form 8-K - Current report
09/5/202422:17GLOBECytoSorbents Reports First Quarter 2024 Results
09/5/202422:14EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06/5/202423:00EDGAR2Form 8-K - Current report
02/5/202413:00GLOBECytoSorbents May 6, 2024 Virtual KOL and Analyst-Investor..
26/4/202413:00GLOBECytoSorbents to Report First Quarter 2024 Operating and..
17/4/202413:00GLOBESTAR-T Pivotal Trial Results to Be Featured as a..
06/3/202413:00GLOBECytoSorbents to Report Fiscal 2023 Operating and Financial..
08/2/202413:00GLOBECytoSorbents to Present at the TD Cowen 44th Annual Health..
17/1/202423:20EDGAR2Form 8-K - Current report
17/1/202413:15GLOBEGroundbreaking Randomized Controlled Trial Reports Excellent..
08/1/202421:00EDGAR2Form SC 13G - Statement of acquisition of beneficial..
28/12/202322:49EDGAR2Form 8-K - Current report
Apertura: 0,91 Min: 0,90625 Max: 0,97
Chiusura: 0,92

La tua Cronologia

NASDAQ
CTSO
CytoSorbents
BIT
UC69D6
Unicredit Bank
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network